Advanced Biomed implements 1-for-20 reverse stock split

Advanced Biomed Inc. (NASDAQ: ADVB) announced a reverse stock split of its common stock at a ratio of 1 for 20 shares, effective at market open on February 20, 2026.

The biotechnology company stated the reverse split aims to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for companies listed on The Nasdaq Capital Market.

Stockholders holding a majority of outstanding voting power approved the reverse split by written consent on January 12, 2026, authorizing ratios between 1 for 2 and 1 for 100 shares. The board approved the 1-for-20 ratio on January 30, 2026.

Following the consolidation, each 20 shares of common stock with a par value of $0.001 will combine into one share maintaining the same par value. The company's total outstanding shares will decrease from 27,290,710 to approximately 1,364,536 shares, while authorized shares remain unchanged.

Trading will continue under the "ADVB" symbol with a new CUSIP number, 00752P203. No fractional shares will be issued, with stockholders receiving one full share in lieu of any fractional share. The reverse split will not alter stockholders' percentage ownership interests, except for minimal changes from fractional share treatment.

Advanced Biomed, based in Tainan City, Taiwan, develops biomedical products for precision medicine and diagnostics. The company operates through a Taiwan subsidiary and has developed a microfluidic platform for circulating tumor cell detection and analysis.

No action is required from stockholders holding shares through brokerage accounts, according to the company's statement.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• Upexi receives Nasdaq minimum bid price deficiency notice
• Amgen reports data breach involving patient and proprietary data